{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:36Z","timestamp":1790712756608,"version":"4.1.0"},"reference-count":22,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Background: Tumor necrosis factor-alpha (TNF-\u03b1), IL-12\/23, IL-17A, and IL-17F are key proinflammatory cytokines involved in the pathogenesis of psoriasis. Biologic therapies targeting these interleukins have demonstrated clinical efficacy. However, the exact relationship between their serum levels and clinical response remains unclear. The aims of this study are to assess changes in cytokine levels (TNF-\u03b1, IL-12\/23, IL-17A, IL-17F) after 12 weeks of biologic treatment in psoriasis to test if there is any correlation between their serum level and PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life Quality Index) scores before or after treatment and to check the influence of clinical and lifestyle factors on these levels. Methods: In this prospective study, 36 patients with moderate-to-severe plaque psoriasis receiving anti-TNF-\u03b1, anti-IL-17, or anti-IL-23 therapy were assessed at baseline and after 12 weeks. The serum levels of these cytokines were measured using the ELISA technique. Clinical response was evaluated using PASI and DLQI scores. Spearman correlation analysis was used to assess the relationship between interleukins\u2019 serum levels and these scores. Results: A significant decrease in TNF-\u03b1 levels and DLQI and PASI scores was observed after 12 weeks across all treatments. A moderate positive correlation (r = 0.391, p = 0.018) was found between serum TNF-\u03b1 levels and PASI scores at week 12. Conclusions: The serum levels of TNF-\u03b1 are significantly correlated with PASI scores following 12 weeks of biologic therapy, supporting their potential role as a biomarker for monitoring treatment efficacy in psoriasis.<\/jats:p>","DOI":"10.3390\/cimb47050368","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:31:29Z","timestamp":1747636289000},"page":"368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of TNF-\u03b1, IL-12\/23, and IL-17 in Psoriasis: Only TNF-\u03b1 Reflects Clinical Response After 12 Weeks of Biologic Treatment"],"prefix":"10.3390","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-0787","authenticated-orcid":false,"given":"Alessandra-M\u0103d\u0103lina","family":"Matei-Man","sequence":"first","affiliation":[{"name":"Dermatology Department, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-3526","authenticated-orcid":false,"given":"\u0218tefan Cristian","family":"Vesa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8817-3914","authenticated-orcid":false,"given":"Alexandra Dana","family":"Pu\u0219ca\u0219","sequence":"additional","affiliation":[{"name":"Independent Researcher, 1021 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meda Sandra","family":"Or\u0103san","sequence":"additional","affiliation":[{"name":"Physiopathology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Homorozeanu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeta","family":"Candrea","sequence":"additional","affiliation":[{"name":"Dermatology Department, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Mocan","sequence":"additional","affiliation":[{"name":"Physiology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cruz, C.J.G., and Yang, C.-C. (2023). Clinical Application of Serum Biomarkers for Detecting and Monitoring of Chronic Plaque Psoriasis. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1196323"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/ijd.ijd_167_24","article-title":"Biomarkers in Psoriasis: The Future of Personalised Treatment","volume":"69","author":"Kar","year":"2024","journal-title":"Indian J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Man, A.-M., Or\u0103san, M.S., Hoteiuc, O.-A., Ol\u0103nescu-Vaida-Voevod, M.-C., and Mocan, T. (2023). Inflammation and Psoriasis: A Comprehensive Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216095"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liu, X.-Q., Zhou, P.-L., Yin, X.-Y., Wang, A.-X., Wang, D.-H., Yang, Y., and Liu, Q. (2023). Circulating Inflammatory Cytokines and Psoriasis Risk: A Systematic Review and Meta-Analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0293327"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/ijd.ijd_79_22","article-title":"Cytokine Profiles and the Relationship of Disease Severity in Patients with Psoriasis","volume":"67","author":"Wang","year":"2022","journal-title":"Indian J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1203475415584503","article-title":"IL-17A, IL-22, and IL-23 as Markers of Psoriasis Activity: A Cross-Sectional, Hospital-Based Study","volume":"19","author":"Fotiadou","year":"2015","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1155\/2013\/856056","article-title":"Serum Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients","volume":"35","author":"Kowal","year":"2013","journal-title":"Dis. Markers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"467541","DOI":"10.1155\/2014\/467541","article-title":"Serum Levels of TNF-\u03b1, IL-12\/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity","volume":"2014","author":"Kyriakou","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5114\/ada.2018.77665","article-title":"The Level of Proinflammatory Cytokines: Interleukins 12, 23, 17 and Tumor Necrosis Factor \u03b1 in Patients with Metabolic Syndrome Accompanying Severe Psoriasis and Psoriatic Arthritis","volume":"35","author":"Pirowska","year":"2018","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_10","first-page":"e938277-1","article-title":"Multiple Cytokine Analysis of Th1\/Th2\/Th9\/Th17\/Th22\/Treg Cytokine Pathway for Individual Immune Profile Assessment in Patients with Psoriasis","volume":"28","author":"Raczkiewicz","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 Has an Anti-Inflammatory Action in Psoriasis and Its Expression Correlates with Disease Severity and Therapeutic Response to Anti-IL-17A Treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13405","DOI":"10.1111\/srt.13405","article-title":"The Effect of Secukinumab Treatment for Psoriasis on Serum Cytokines and Correlation with Disease Severity","volume":"29","author":"Wu","year":"2023","journal-title":"Skin Res. Technol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2787954","DOI":"10.1155\/2022\/2787954","article-title":"Profiling Serum Cytokines and Anticytokine Antibodies in Psoriasis Patients","volume":"2022","author":"Hong","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5114\/ada.2020.100481","article-title":"Interleukin 22 and 6 Serum Concentrations Decrease under Long-Term Biologic Therapy in Psoriasis","volume":"37","author":"Narbutt","year":"2020","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/1346-8138.15278","article-title":"Assessment of Serum Biomarkers in Patients with Plaque Psoriasis on Secukinumab","volume":"47","author":"Morita","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study","volume":"139","author":"Gordon","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Czerwi\u0144ska, J., Kasprowicz-Furma\u0144czyk, M., Placek, W., and Owczarczyk-Saczonek, A. (2022). Changes in Tumor Necrosis Factor \u03b1 (TNF\u03b1) and Peptidyl Arginine Deiminase 4 (PAD-4) Levels in Serum of General Treated Psoriatic Patients. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19148723"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.31925\/farmacia.2023.6.12","article-title":"CHALLENGING CORRELATIONS BETWEEN PSORIASIS SEVERITY AND TNF-\u03b1 LEVELS IN HARD-TO-TREAT AREAS","volume":"71","author":"Nicolescu","year":"2023","journal-title":"Farmacia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., and Yang, S.-H. (2021). The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052719"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Brembilla, N.C., and Boehncke, W.-H. (2023). Revisiting the Interleukin 17 Family of Cytokines in Psoriasis: Pathogenesis and Potential Targets for Innovative Therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1186455"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abd.2023.03.002","article-title":"Elevated Serum IL-6 Levels Predict Treatment Interruption in Patients with Moderate to Severe Psoriasis: A 6-Year Real-World Cohort Study","volume":"99","author":"Kurizky","year":"2024","journal-title":"An. Bras. Dermatol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/5\/368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:17Z","timestamp":1760031257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/5\/368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cimb47050368"],"URL":"https:\/\/doi.org\/10.3390\/cimb47050368","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}